Favorgen
|
|
|
|
Favorgen BiosettiaTM single oligonucleotide RNAi technology (SORT) for gene silencing delivers a unique feature in the construction of shRNA expression vectors. Distinct from any other shRNA expression vectors currently available, only one DNA oligonucleotide is required for cloning a shRNA sequence into the pRNAi or pLV-RNAi vector. The novelty of the pRNAi expression vector system benefits the users with lower cost, higher efficiency, and less complexity. Favorgen also provides updated human miRNA lentiviral collection with 93% completion. This human miRNA lentiviral collection provides the highly efficient tool for functional screening study for the discovery of potential drug targets and biomarkers for diagnostics. Human micro RNA (has-miRNA) precursors and flanking genomic sequences approximately 100 bp upstream and downstream were PCR amplified and cloned into a self-inactivated (SIN) lentiviral vector to generate a lenti-has-miRNA collection. The cloning site of pre-miRNA genomic fragments is within the intron of human EF1α promoter region. The miRNA lentiviral stock was prepared by cotransfecting the lenti-has-miRNA vector with plasmids expression Gag-Pol gene products, and pseudotyped envelope protein-vesicular stomatitis virus envelope G(VSV-G) into HEK 293T cells. The lentiviral supernatants were collected at 48 hours post transfection and stored at -70 ℃. The titer of the virus is generally above 1x 106 IU/ ml . Biosettia pRNAi Vector System-1 |
|
Send mail to
webmaster@gentaur.com with
questions or comments about this web site.
|
+32
1658 9045
+32
1650 9045
